Cellsway is developing a microfluidic liquid biopsy platform that utilizes a simple blood sample to monitor cancer by enriching and identifying circulating tumor cells (CTCs). This minimally invasive approach enables multiple sampling and improved patient profiling, facilitating timely and accurate cancer management.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TIFounders
Product
Problem
Monitoring cancer progression and treatment effectiveness often requires invasive tissue biopsies, posing risks and limiting the frequency of assessment. Traditional methods for detecting circulating tumor cells (CTCs) can be inefficient, failing to capture a sufficient number of these rare cells for comprehensive analysis. This can lead to delays in diagnosis, suboptimal treatment decisions, and reduced opportunities for personalized cancer management.
Solution
Cellsway offers a microfluidic liquid biopsy platform designed to enrich, identify, and characterize circulating tumor cells (CTCs) from a simple blood sample. The platform utilizes a patented microfluidic chip for high-efficiency, size-based CTC enrichment, integrated with downstream assays for comprehensive analysis. This minimally invasive approach enables frequent monitoring of cancer progression, providing clinicians with actionable data for therapy selection, treatment monitoring, and personalized cancer management. The system's in-situ solution facilitates a distributed model in service laboratories, while its user-friendly, fully automated instrument ensures smooth operation with reproducible results and minimal hands-on time.
Target Audience
Cellsway's primary customers are clinical laboratories, oncologists, and researchers involved in cancer diagnostics, treatment monitoring, and personalized medicine.
Features
- High-efficiency CTC enrichment using a patented microfluidic chip
- Fully automated instrument with less than 10 minutes hands-on time
- In-situ solution enabling a distributed model in service laboratories
- CTC identification panel for detection of epithelial CTCs (CD45-, cytokeratin+, DAPI+) by immunofluorescence analysis
- ER/PR/Her2 CTC panel for detection of hormone receptor and human epidermal growth factor receptor 2 in CTCs
- PD-L1 CTC panel for determination of the PD-L1 biomarker in CTCs
- Streamlined workflow for CTC enrichment, identification, and characterization